J Korean Diabetes.  2015 Dec;16(4):236-241. 10.4093/jkd.2015.16.4.236.

Vaccination for Diabetic Patients: An Update

• Yeom JS

• KMID: 2173849
• DOI: http://doi.org/10.4093/jkd.2015.16.4.236

Abstract

As Korean populations are getting older and the number of adults with diabetes is continually increasing, importance of prevention of infectious diseases through vaccination has increased. With recent introduction of newly developed vaccines, especially protein-conjugated pneumococcal vaccine and quadrivalent influenza vaccine, guidelines for adult vaccination that include recommendation for diabetic patients have been revised. In this article, revised adult vaccination guidelines will be review based on recently published results of the effectiveness of protein conjugate pneumococcal vaccine for prevention of pneumonia and that of the quadrivalent influenza vaccine.

Keyword

Diabetes mellitus; Human influenza; Immunization; Pneumococcal infections

MeSH Terms

Adult
Communicable Diseases
Diabetes Mellitus
Humans
Immunization
Influenza Vaccines
Influenza, Human
Pneumococcal Infections
Pneumonia
Vaccination*
Vaccines
Influenza Vaccines
Vaccines

Figure

• 

  Fig. 1. Recommendations on pneumococcal vaccine for adults 65 years of age or older with a chronic medical condition. Reused from the article of Choi et al. (Infect Chemother 2015;47:68–79) [9] with original copyright holder's permission. PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine.

Reference

References

1. Korea Diabetes Association, Korea Center for Disease Control and Prevention. Diabetes fact sheet in Korea. Available from:. http://www.diabetes.or.kr/temp/Diabetes_Fact_sheet2012.pdf. (accessed 2015 Nov 1).

2. Joo EJ, Yeom JS. Adult immunization in patients with diabetes mellitus: current immunization status and recommended schedule in Korea. J Korean Diabetes. 2013; 14:103–10.

3. Song JY, Choi JY, Lee JS, Bae IG, Kim YK, Sohn JW, Jo YM, Choi WS, Lee J, Park KH, Kim WJ, Cheong HJ. Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study. BMC Infect Dis. 2013; 13:202.

4. Kim ES, Park YJ, Park O. Elderly immunization program against invasive pneumococcal disease in Korea, 2014. Public Health Wkly Rep. 2015; 8:366–8.

5. Vila-Corcoles A, Ochoa-Gondar O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging. 2013; 30:263–76.

6. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults.

7. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372:1114–25.

8. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014; 63:822–5.

9. Choi WS, Choi JH, Kwon KT, Seo K, Kim MA, Lee SO, Hong YJ, Lee JS, Song JY, Bang JH, Choi HJ, Choi YH, Lee DG, Cheong HJ. Committee of Adult Immunization; Korean Society of Infectious Diseases. Revised adult immunization guideline recommended by the Korean society of infectious diseases, 2014. Infect Chemother. 2015; 47:68–79.

10. Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. Vaccine. 2014; 32:2364–74.

11. Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013; 31:3594–602.

12. Noh JY, Kim WJ. Influenza vaccines: unmet needs and recent developments. Infect Chemother. 2013; 45:375–86.

13. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012; 8:81–8.

14. Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999–2012. Clin Infect Dis. 2014; 59:1519–24.

15. Korea Centers for Disease Control & Prevention. Korean influenza sentinel surveillance report, 2013–2014. Public Health Wkly Rep. 2014; 7:1089–98.

16. Eurosurveillance Editorial Team. WHO recommendations on the composition of the 2013/14 influenza virus vaccines in the northern hemisphere. Euro Surveill. 2013; 18:pii: 20411.

17. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis. 2013; 13:343.

18. Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013; 31:5572–8.

19. Jain VK, Rivera L, Zaman K, Espos RA Jr, Sirivichayakul C, Quiambao BP, Rivera-Medina DM, Kerdpanich P, Ceyhan M, Dinleyici EC, Cravioto A, Yunus M, Chanthavanich P, Limkittikul K, Kurugol Z, Alhan E, Caplanusi A, Durviaux S, Boutet P, Ofori-Anyinam O, Chandrasekaran V, Dbaibo G, Innis BL. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med. 2013; 369:2481–91.

20. You JH, Ming WK, Chan PK. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong: a decision analysis. Hum Vaccin Immunother. 2015; 11:564–71.

21. Chit A, Roiz J, Aballea S. An assessment of the expected cost-effectiveness of quadrivalent influenza vaccines in Ontario, Canada using a static model. PLoS One. 2015; 10:e0133606.

22. Thommes EW, Ismaila A, Chit A, Meier G, Bauch CT. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. BMC Infect Dis. 2015; 15:465.